AIMC Topic: Rituximab

Clear Filters Showing 11 to 14 of 14 articles

Prediction of immunochemotherapy response for diffuse large B-cell lymphoma using artificial intelligence digital pathology.

The journal of pathology. Clinical research May 1, 2024
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous and prevalent subtype of aggressive non-Hodgkin lymphoma that poses diagnostic and prognostic challenges, particularly in predicting drug responsiveness. In this study, we used digital patholog...
Humans Artificial Intelligence Retrospective Studies Reproducibility of Results Lymphoma, Large B-Cell, Diffuse Antineoplastic Combined Chemotherapy Protocols Cyclophosphamide Rituximab
View on PubMed DOI

Deep learning-based classifier of diffuse large B-cell lymphoma cell-of-origin with clinical outcome.

Briefings in functional genomics Jan 20, 2023
Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma with poor response to R-CHOP therapy due to remarkable heterogeneity. Based on gene expression, DLBCL cases were divided into two subtypes, i.e. ABC and GCB, where AB...
Humans Lymphoma, Large B-Cell, Diffuse Deep Learning Cyclophosphamide Rituximab Genetic Techniques
View on PubMed DOI

Serum 25-hydroxyvitamin D levels in patients with Granulomatosis with Polyangiitis: association with respiratory infection.

Clinics (Sao Paulo, Brazil) Dec 1, 2017
OBJECTIVES: To determine the possible association of serum 25-hydroxyvitamin D (25OHD) levels with disease activity and respiratory infection in granulomatosis with polyangiitis patients during two different periods: winter/spring and summer/autumn.
Humans Biomarkers Female Adult Male Middle Aged Vitamin D Immunosuppressive Agents Seasons Respiratory Tract Infections Granulomatosis with Polyangiitis Prednisone Rituximab
View on PubMed DOI

Doxorubicin enhances (131)I-rituximab induced cell death in Raji cells.

Journal of cancer research and therapeutics Jan 1, 2015
AIM: There are various therapeutic modalities of treatment for non-Hodgkin's lymphoma, but with certain limitations, hence, investigating the scope of combined therapeutic approach.
Humans RNA, Messenger Cell Proliferation Signal Transduction Antineoplastic Combined Chemotherapy Protocols Apoptosis Blotting, Western Flow Cytometry Radiopharmaceuticals Doxorubicin Iodine Radioisotopes Drug Synergism Tumor Cells, Cultured Rituximab Poly(ADP-ribose) Polymerases Burkitt Lymphoma Radiation-Sensitizing Agents
View on PubMed DOI
Popular Topics
Recent Journals